Neurology® Journals Disclosure Guidelines

- In the Disclosure section of the manuscript, all authors’ financial relationships (and those of their “immediate family members”) from the past two years must be disclosed if they are deemed relevant to the study described in the submitted manuscript. If the study period of the submitted manuscript exceeded two years, financial relationships relevant to the topic must also be disclosed.
- (Authors will be notified at the appropriate time to complete an online Disclosure Agreement Form with all financial relationships [and those of their immediate family members] from the past two years regardless of whether these relationships are related to the study described in the submitted manuscript. If the study period of the submitted manuscript exceeded two years, financial relationships relevant to the topic must also be disclosed. The Disclosure Form information will be published online with article.)
- This disclosure will appear on the title page.
- Mention any corporate sponsorship of the study first. Mention government or institutional funding second.
- No dollar amount or years need to be included because they will not be published. However, the online form will request authors to input years.
- Order author names as they appear in the manuscript byline.
- Structure of sentences should be as similar as possible to example below. If relationship is ongoing, use present tense; if relationship is from an earlier period, use past tense.
- The corresponding author is responsible for ensuring that full disclosures appear on the submitted, revised, and final accepted manuscripts and that the page proofs reflect the disclosures listed.

EXAMPLES OF DISCLOSURES

This study was sponsored by Biotech Pharmaceuticals.

J. R. Wu served on the scientific advisory board for Sirex Pharmaceuticals, performs neuroimaging in his clinical practice (65% effort) and bills for this procedure, is funded by NIH grants #0H860-97 and #0H920-72, and received research support from the Muscular Dystrophy Association.

H. Jacobsen reports no disclosures.

R.S. Applebaum serves as an editorial board member of Genetic Study, receives royalties from BioTechnic Corp., holds stock options from BioTechnic Corp. which sponsored research for which he served as primary investigator, received research support from BioTechnic Corp., and received institutional support from the University of Indiana for genetics research.

J. Black is a consultant for Sirex Pharmaceuticals, received funding for a trip from Jenson Pharmaceuticals, holds stock options in Loring Pharma for serving on its Board of Directors, and receives revenue from MediHealth, Inc. for a patent.

S. T. Williams received honoraria from serving on the scientific advisory board of Advent Pharmaceuticals, administers botulinum toxin in his clinical practice (35% effort) and bills for this practice, served as a consultant in the trial Alexander v. Joseph, and received contractual rights from OptiVisor Inc., which has been licensed.

T. J. Bloch and Mrs. Bloch (wife) hold stock options in Gena Pharmaceuticals. T. Bloch receives license fee payments from Gena Pharmaceuticals and provided an affidavit for the trial Abry v. United Labor Force.